News about Biotechnology, Pharmaceutical and Healthcare

20:12 EDT 30th March 2015 | BioPortfolio

Latest news articles in the life-science, healthcare, medical device, biotechnology and pharmaceuticals sectors. 

Showing News Articles 1–25 of 7,400+

Monday 30th March 2015

CRN: GNC, NY AG agreement a 'disservice to consumers'

Michael JohnsenThe supplement industry criticized the agreement between GNC and the New York Attorney General's office.  read more

UnitedHealth Group beefs up PBM business with merger agreement

Antoinette AlexanderOptumRx, UnitedHealth Group’s freestanding pharmacy care services business, ramps up PBM business with a $12.8 billion deal. read more

Carmex survey: Cold sores kill first impressions

Michael JohnsenHalf of adults would say "no way" to meeting someone for a date if they had a cold sore, according to a Carmex survey.  read more

Study: Mobile holiday traffic peaked Thanksgiving, hit low Cyber Monday

Dan BerthiaumeMobile traffic during the 2014 holiday season peaked on Thanksgiving (50% of online traffic) and hit a low point on Cyber Monday (30% of online traffic). read more

DRYPro launches cast protector with customizable logo option

Michael JohnsenDRYPro is launching a sealable, waterproof cast protector. read more

Coming soon to Sam's Club: 3-D printers

MakerBot is coming to an even wider mass market arena as the 3-D printer rolls out at more than 300 Sam's Club locations in the United States. read more

Patients can stop taking statins in terminal care, research suggests

Discontinuing statin use in patients with late-stage terminal illnesses is safe and may even be beneficial, according to research in JAMA Internal Medicine.

Vernon Thompson dies

On 22 February 2015, Vernon Thompson, aged 86, of Folly Road, Mildenhall, Suffolk IP28 7AD. Mr Thompson registered with the Society in 1953 and left in 2005.

HPV vaccine Gardasil 9 is approved by European drug regulator

A human papillomavirus vaccine that protects against nine different strains of the virus has been given preliminary approval by the European Medicines Agency.

APhA Foundation endows the William H. Briner Award with support from the National Association of Nuclear Pharmacies

Antoinette AlexanderThe American Pharmacists Association Foundation has announced the completed endowment of the APhA-Academy of Pharmacy Practice and Management William H. Briner Distinguished Nuclear Pharmacy Practice Award with a pledge from the National Association of Nuclear Pharmacies. read more

Delhaize Group completes sale of Bottom Dollar

Antoinette AlexanderDelhaize Group has completed the sale of its Bottom Dollar Food store locations to ALDI, enabling the grocer to focus on its core markets. read more

Teva to strengthen CNS portfolio with Auspex acquisition

Ryan ChavisTeva Pharmaceutical Industries and Auspex Pharmaceuticals announced an agreement under which Teva will acquire Auspex in a deal valued at $3.2 billion. read more

Addressing the adherence gap

Poor medication use in patients with long-term health conditions is widely recognised as a global problem that urgently needs to be addressed, but there is still debate about the best ways of doing this. During my 30 years’ experience I have investigated the influence of psychological processes on health, illness and health care delivery. The main focus of this has been on the ways in which pati...

Alpina Foods rolls out coffee-infused yogurt

Ryan ChavisAlpina Foods on Monday announced the launch of a line of yogurts infused with coffee. read more

Utrogestan excipient change

Utrogestan (progesterone; Besins Healthcare) oral capsules 100mg now contain sunflower oil as an excipient. Arachis oil is no longer included. More information on 01672 516885.

Chloromycetin out of stock

Chloromycetin Redidrops (chloramphenicol) eye drops 0.5%w/v x 5ml are out of stock from Amdipharm Mercury and are due back in stock by August 2015.

Bupivacaine and adrenaline, ferrous fumarate and ropivacaine out of stock

The following products are out of stock from Amdipharm Mercury and are due back in stock by May 2015: bupivacaine and adrenaline injection 0.25%w/v, 1 in 200,000, 10ml x 10; ferrous fumarate tablets 210mg x 84; and ropivacaine solution for injection 10mg/ml, 7.5mg/ml and 2mg/ml, all 10ml x 10.

Alfacalcidol, Maloxon and phenoxybenzamine out of stock

The following products are currently out of stock from Amdipharm Mercury and are due back in stock by the end of April 2015: alfacalcidol capsules 0.25μg x 30 and 1μg x 30; Maloxon (metoclopramide hydrochloride) tablets 10mg x 84; and phenoxybenzamine capsules 10mg x 30.

Crohn’s disease investigational drug shows promise, phase II trial shows

Mongersen, an investigational agent being developed by Celgene, has been tested in Crohn’s disease and researchers have seen clinical remission in some patients.

UK to become first country to offer meningococcal B vaccine to babies

The meningococcal B (MenB) vaccine is to be added to the UK’s national childhood immunisation programme, likely from September 2015.

NY AG's office affirms GNC supplements in full compliance with FDA regs

Michael JohnsenGNC on Monday announced an agreement with the New York Attorney General's office affirming that all of the products called into question by the office were actually in full compliance with cGMPs.  read more

No more waiting for the Sun: FTC approves $4bn Ranbaxy acquisition

Sun Pharmaceutical Industries has completed its $4bn (€3.7bn) acquisition of Ranbaxy after receiving the thumbs up from the US Federal Trade Commission (FTC).

Lilly says Indy Religious Freedom law is discriminatory and may hamper cancer and AD drug development

Indiana’s new “religious freedom” law is discriminatory and will make it harder to attract the staff needed to develop drugs for cancer and Alzheimer's disease according to Eli Lilly.

Promoting medical innovation as a pharmaceutical scientist

Zahid Latif has worked in drug discovery projects across the UK and now leads efforts to promote innovative medical research collaborations between industry and academia.

Tildrakizumab shows promise as psoriasis treatment

Merck reports in a phase I trial that its new monoclonal antibody, tildrakizumab, reduces psoriasis symptoms.


Search BioPortfolio:
Loading
Advertisement
Advertisement